glp 1 drug coverage What to Make of the GLP-1 and Cost Landscape McKee's proposed FY2027 budget drops

A gradual step-down gives the researcher time to implement dietary and behavioral strategies at each lower dose level, building habits that can partially compensate for the loss of pharmacological support

[DOI] [Google Scholar] 233.Liang Y, et al

Here is what has occurred and what patients may expect in the coming months based on manufacturer announcements and regulatory filings: December 22, 2025: FDA approved oral Wegovy (semaglutide 25 mg), the first oral GLP-1 for weight loss

In order to improve fiber intake during a caloric deficit with reduced appetite, prioritizing the highest-fiber food sources (avocado, chia seeds, pears, berries, legumes) alongside fiber supplementation will help to mitigate the constipation experienced with GLP-1 agonists while supporting the therapeutic goal of satiety and blood glucose regulation

It is increasingly recognised that obesity leads to increased CVD mortality independent of cardiovascular risk factors

Hemodynamic disturbances play a central role in DKD progression